Cellectis SA (NASDAQ:CLLS) Expected to Post Earnings of -$0.76 Per Share

Brokerages expect Cellectis SA (NASDAQ:CLLS) to announce earnings of ($0.76) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Cellectis’ earnings. The lowest EPS estimate is ($0.97) and the highest is ($0.57). Cellectis posted earnings per share of ($0.36) in the same quarter last year, which would indicate a negative year over year growth rate of 111.1%. The company is scheduled to issue its next quarterly earnings results on Tuesday, November 12th.

According to Zacks, analysts expect that Cellectis will report full-year earnings of ($2.68) per share for the current year, with EPS estimates ranging from ($3.08) to ($2.06). For the next fiscal year, analysts anticipate that the business will post earnings of ($2.60) per share, with EPS estimates ranging from ($3.95) to ($1.47). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Cellectis.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.18). The firm had revenue of $2.93 million during the quarter, compared to analyst estimates of $3.45 million. Cellectis had a negative return on equity of 21.51% and a negative net margin of 813.06%.

CLLS has been the topic of several recent research reports. Citigroup reaffirmed a “neutral” rating and set a $22.00 price objective on shares of Cellectis in a research report on Friday, May 24th. Zacks Investment Research lowered shares of Cellectis from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. Goldman Sachs Group set a $20.00 price objective on shares of Cellectis and gave the company a “hold” rating in a research report on Monday, August 12th. BTIG Research started coverage on shares of Cellectis in a research report on Friday, August 9th. They issued a “buy” rating and a $37.00 price target on the stock. Finally, BidaskClub lowered shares of Cellectis from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 17th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the stock. Cellectis has a consensus rating of “Hold” and an average target price of $31.67.

CLLS traded down $0.42 during midday trading on Friday, hitting $12.09. 2,907 shares of the company’s stock traded hands, compared to its average volume of 123,225. The company has a market cap of $519.17 million, a PE ratio of -6.27 and a beta of 1.72. The stock’s fifty day simple moving average is $14.55 and its 200-day simple moving average is $17.04. The company has a debt-to-equity ratio of 0.11, a current ratio of 8.47 and a quick ratio of 8.46. Cellectis has a one year low of $11.70 and a one year high of $29.97.

Several hedge funds and other institutional investors have recently modified their holdings of the business. Financial Gravity Wealth Inc. bought a new position in shares of Cellectis during the first quarter valued at $96,000. Cubist Systematic Strategies LLC bought a new position in shares of Cellectis during the second quarter valued at $103,000. Eqis Capital Management Inc. lifted its holdings in shares of Cellectis by 24.1% during the first quarter. Eqis Capital Management Inc. now owns 43,941 shares of the biotechnology company’s stock valued at $806,000 after acquiring an additional 8,545 shares during the period. Aperio Group LLC bought a new position in shares of Cellectis during the second quarter valued at $147,000. Finally, A.R.T. Advisors LLC bought a new position in shares of Cellectis during the second quarter valued at $171,000. 31.95% of the stock is owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.

Further Reading: How to calculate the intrinsic value of a stock

Get a free copy of the Zacks research report on Cellectis (CLLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.